Latest news with #BIO2025
Business Upturn
21-06-2025
- Business
- Business Upturn
Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) — Saudi Arabia has concluded its landmark debut at the BIO International Convention 2025, having signed more than a dozen partnerships, launched a national biotech accelerator program with Biolabs and established the Kingdom as a global hub for life sciences. Over four days, Saudi delegates showcased an ecosystem ready for collaboration across scientific discovery, clinical research, and advanced therapeutics. The Kingdom's presence spanned the entire biotech value chain – from early research to manufacturing, from regulatory frameworks to commercialization pathways. 'Saudi Arabia is stepping into biotech with intention and scale,' said His Excellency the Vice Minister of Health for Planning and Development, Eng. Abdulaziz AlRamaih. 'Biotech sits at the intersection of our health transformation and economic ambition, and we are investing with that dual mandate in mind.' Partnerships and Programs Take Center Stage Throughout the week, Saudi Arabia hosted one of the most active national pavilions at the conference, convening more than 25 entities across government, research, investment and innovation. More than a dozen new memoranda of understanding were signed with international partners, including leaders in genomics, AI-enabled diagnostics, gene therapy, and biomanufacturing. The Ministry of Health also formally launched its national biotech accelerator program in collaboration with BioLabs, welcoming an inaugural cohort of eight Saudi-founded biotech startups in areas ranging from protein engineering to precision genomics. The launch event brought together venture capitalists, researchers, and biotech executives to discuss the Kingdom's innovation momentum. The Kingdom's Super Session at BIO 2025 featured senior representatives from the Ministry of Health (MoH), the Saudi Food and Drug Authority (SFDA), the Saudi National Institute for Health (SNIH), the King Abdullah International Medical Research Center (KAIMRC), the King Faisal Specialist Hospital and Research Centre (KFSH&RC), and the Public Investment Fund (PIF). The panel revealed how Saudi Arabia is coordinating across policy, clinical infrastructure, and public investment to create a biotech ecosystem built for scale and scientific depth. In parallel, the delegation held more than 50 one-to-one meetings with global biotech firms and visited U.S. innovation hubs to explore collaboration in research, manufacturing, and translational medicine. The Kingdom also participated in a dedicated gathering for Saudi research talent studying in the United States, underscoring the Kingdom's long-term commitment to human capital in health and life sciences. Advancing Genomics and Genetic Medicine The Kingdom's ambition in genomics also drew significant interest. Through the Saudi Genome Program, the Kingdom has developed one of the region's most comprehensive population-specific genomic datasets, paving the way for earlier diagnosis, localized drug development, and new therapeutic approaches for inherited diseases. National screening efforts – led by Saudi Arabia's Public Health Authority, Weqaya – are expanding access to genetic risk detection through prenatal and newborn programs. Institutions like KFSH&RC and KAIMRC continue to drive forward clinical trials and translational research, supporting a growing pipeline of personalized treatments rooted in real-world data. Already, over 130 peer-reviewed publications have leveraged Saudi genomic data to inform rare disease research and advance precision diagnostics. The Kingdom's cell and gene therapy readiness now spans regulation, clinical trials, and talent development, with the Saudi Food and Drug Authority's fast-track approval of advanced therapies positioning it as one of the world's most agile regulators. A Platform for the Future Under the National Biotechnology Strategy, with the continued support of HRH Prince Mohammed bin Salman, Crown Prince and Prime Minister, Saudi Arabia is making biotech central to its national transformation, and the health and economic prosperity of its people. The Kingdom concludes BIO 2025 with a clear message: Saudi Arabia is open for collaboration, primed for innovation, and committed to lasting partnerships. About Saudi Biotech The Kingdom of Saudi Arabia was proud to debut its first-ever national pavilion at BIO International, being held in Boston June 16-19, 2025. Rooted in Vision 2030, this initiative showcased a fully integrated life sciences ecosystem – combining a future-ready lifestyle, world-class research institutions, streamlined regulation, and digital infrastructure built for speed, scale, and scientific impact. The Kingdom offers a seamless environment for biotech innovation with fast-track clinical trial approvals, robust regulatory alignment via its ML4-designated Food and Drug Authority, and nationwide digital platforms like NPHIES and the world's largest Virtual Hospital. Saudi Biotech brings together the Kingdom's leading health and science entities, including the Ministry of Health, Saudi Food and Drug Authority, Saudi National Institute of Health, Public Health Authority, and the Saudi Health Council, all of whom play vital roles in enabling a regulatory environment that supports clinical innovation. It also features institutions powering translational research and IP protection, such as the Research, Development and Innovation Authority, King Faisal Specialist Hospital and Research Centre, King Abdulaziz City for Science and Technology, King Abdullah University of Science and Technology, and the King Abdullah International Medical Research Center. Funding and investment facilitators were also present, including the Ministry of Investment, Ministry of Industry and Mineral Resources, and the Saudi Business Center, alongside localization powerhouses like Lifera, Lean, and the Public Investment Fund. Visitors had the opportunity to explore how talent and livability are central to the Kingdom's strategy through participation from the Royal Commission for Riyadh City and the Premium Residency Center. Finally, NEOM showcased the Kingdom's most ambitious vision – a purpose-built frontier for biotech, precision medicine, and future health. Visit to learn more. Contact:Saudi Biotech [email protected]
India Today
19-06-2025
- Business
- India Today
Priyank Kharge accuses External Affairs Ministry of bias in US visit clearance
Karnataka's Information Technology Minister Priyank Kharge raised strong objections after reportedly being denied clearance by India's Ministry of External Affairs (MEA) to travel to the United States for an official investment out on the issue, Kharge questioned the MEA's rationale for blocking his participation. 'The delegation with my name doesn't get clearance from MEA, the same delegation without my name gets clearance. Why this disparity?' he Congress leader was slated to lead a delegation from the state to attend the prestigious BIO 2025 conference in Boston and the Design and Automation Conference in San Francisco. Kharge clarified that this was not a last-minute visit. 'It was a pre-planned official visit on behalf of the state government, supported by the Centre. We sent the request with a minute-to-minute programme on May 15,' he said. The proposal included the minister and accompanying on June 4, MEA responded with a denial, without any stated reason. Subsequently, Kharge removed his name from the list and resubmitted the request with only officers. The revised delegation received approval on June 11. 'The request was exactly the same, just without my name,' he pointed he said that when he proposed Sharath Bachegowda, Chairman of KIONICS, as a replacement on June 12, clearance was granted by June 14. 'So you see the pattern here,' Kharge minister plans to formally write to the MEA seeking an explanation. 'The Chief Minister will also write to the Prime Minister. This government has already outsourced our foreign policy, now they are outsourcing our investment policy,' he remarked. IN THIS STORY#Karnataka
CairoScene
18-06-2025
- Health
- CairoScene
Over 25 Saudi Health Groups Spotlight Biotech Innovation at BIO Boston
Saudi Arabia's national pavilion at BIO 2025 features over 25 groups in health and science, spotlighting research potential and global biotech partnerships from June 16th to the 19th in Boston. Saudi Arabia is participating in the 2025 BIO International Convention in Boston with a national pavilion led by the Ministry of Health. The Kingdom's delegation includes more than 25 organisations from across the government, private sector, and research community, marking one of its largest representations at the global biotech summit to date. The delegation is taking part in exhibitions and high-level meetings focused on advancing biotechnology research, development, and investment. The event, widely recognised as the world's largest gathering of stakeholders in life sciences and medical innovation, runs through June 19th. Saudi Arabia's presence aligns with its recently launched National Biotechnology Strategy, a key pillar of the country's broader push to expand its role in science, medicine, and high-tech industries. The strategy forms part of Saudi Vision 2030, which outlines major health sector transformation programmes and aims to position the Kingdom as a global hub for innovation. The BIO Convention, hosted this year in Boston—a major centre for life sciences—offers a strategic platform for the Kingdom to showcase its advancements and attract international collaboration in emerging biotech fields.
India Today
17-06-2025
- Business
- India Today
Priyank Kharge denied clearance for US trip: Will seek explanation from government
Karnataka's Information Technology and Biotechnology Minister Priyank Kharge was reportedly denied the necessary clearances to the United States on Kharge was scheduled to lead the state delegation at BIO 2025 in Boston and the Design and Automation Conference in San Congress leader was expected to travel with the official team representing the state's tech ecosystem. However, the required clearances did not materialise in time, forcing him to drop out of the delegation. The nature of the delay—whether due to a procedural hold-up by India's Ministry of External Affairs (MEA) or an issue on the US side—remains Taking to social media platform X, Kharge said, 'I'm holding back on making any public statements for now. Once I'm back in Bengaluru, I will seek a clear explanation from the Government of India regarding this denial.'The minister had earlier attended a conference and Aero Show in Paris, representing Watch
The Sun
17-06-2025
- Business
- The Sun
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
HONG KONG SAR - Media OutReach Newswire - 17 June 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) - to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: • Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. • HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: 'We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation.' Ahead of BIO 2025, the delegation participated in the '2025 Biomedical Pitch Competition', co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as 'Edison of Medicine'), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: 1. Allegrow Biotech Limited 2. ARBELE Limited 3. Beth Bioinformatics Co., Limited 4. Centre for Translational Stem Cell Biology 5. The Centre for Virology, Vaccinology, and Therapeutics 6. DECODE CURE Limited 7. GenEditBio Limited 8. Great Bay Bio 9. Hong Kong Universal Biologicals Company Limited 10. Immuno Cure Holding (HK) Limited 11. The Institute for Innovation, Translation and Policy Research (ITPR) 12. LEE'S PHARMACEUTICAL (HK) LIMITED 13. Serilink Biotechnology Company Limited 14. Xiaomo Biotech Limited 15. XUXIN (HongKong) Biotechnology Co., Limited 16. Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP
